Michael A. Nauck
Diabeteszentrum Bad Lauterberg
Bad Lauterberg im Harz
Germany
Name/email consistency: high
- Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down? Nauck, M.A., Vardarli, I., Deacon, C.F., Holst, J.J., Meier, J.J. Diabetologia (2011)
- Unraveling the science of incretin biology. Nauck, M.A. Eur. J. Intern. Med. (2009)
- Self-monitoring of blood glucose in diabetes mellitus: arguments for an individualized approach. Nauck, M.A., El-Ouaghlidi, A., Vardarli, I. Dtsch. Arztebl. Int (2009)
- Unraveling the science of incretin biology. Nauck, M.A. Am. J. Med. (2009)
- Incretin-based therapy: how do incretin mimetics and DPP-4 inhibitors fit into treatment algorithms for type 2 diabetic patients? Nauck, M., Smith, U. Best Pract. Res. Clin. Endocrinol. Metab. (2009)
- Incretin-based therapies: viewpoints on the way to consensus. Nauck, M.A., Vilsbøll, T., Gallwitz, B., Garber, A., Madsbad, S. Diabetes. Care (2009)
- Hypoglycemia due to paraneoplastic secretion of insulin-like growth factor-I in a patient with metastasizing large-cell carcinoma of the lung. Nauck, M.A., Reinecke, M., Perren, A., Frystyk, J., Berishvili, G., Zwimpfer, C., Figge, A.M., Flyvbjerg, A., Lankisch, P.G., Blum, W.F., Klöppel, G., Schmiegel, W., Zapf, J. J. Clin. Endocrinol. Metab. (2007)
- The enteroinsular axis may mediate the diabetogenic effects of TCF7L2 polymorphisms. Nauck, M.A., Meier, J.J. Diabetologia (2007)
- Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes. Nauck, M.A., Hompesch, M., Filipczak, R., Le, T.D., Zdravkovic, M., Gumprecht, J. Exp. Clin. Endocrinol. Diabetes (2006)
- The therapeutic actions of DPP-IV inhibition are not mediated by glucagon-like peptide-1. Nauck, M.A., El-Ouaghlidi, A. Diabetologia (2005)
- Glucagon-like peptide 1 and its derivatives in the treatment of diabetes. Nauck, M.A., Meier, J.J. Regul. Pept. (2005)
- Blood glucose control in healthy subject and patients receiving intravenous glucose infusion or total parenteral nutrition using glucagon-like peptide 1. Nauck, M.A., Walberg, J., Vethacke, A., El-Ouaghlidi, A., Senkal, M., Holst, J.J., Gallwitz, B., Gallwitz, J.B., Schmidt, W.E., Schmiegel, W. Regul. Pept. (2004)
- Gastric inhibitory polypeptide and glucagon-like peptide-1 in the pathogenesis of type 2 diabetes. Nauck, M.A., Baller, B., Meier, J.J. Diabetes (2004)
- Glucagon-like peptide 1 (GLP-1) in the treatment of diabetes. Nauck, M.A. Horm. Metab. Res. (2004)
- Incretins and their analogues as new antidiabetic drugs. Nauck, M.A., Meier, J.J., Creutzfeldt, W. Drug News Perspect. (2003)
- Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. Nauck, M.A., Heimesaat, M.M., Behle, K., Holst, J.J., Nauck, M.S., Ritzel, R., Hüfner, M., Schmiegel, W.H. J. Clin. Endocrinol. Metab. (2002)